A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

NCT07477587 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

258

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma (MM)

Interventions

DRUG: HLX15-SC-Rd
DRUG: US-DARZALEX FASPRO®-Rd

Sponsor

Shanghai Henlius Biotech